Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2551Triple Negative Breast Neoplasms 436Carcinoma, Non-Small-Cell Lung 339Ovarian Neoplasms 315Neoplasms 281Neoplasm Metastasis 253Colorectal Neoplasms 246Stomach Neoplasms 202Pancreatic Neoplasms 196Prostatic Neoplasms 188Lung Neoplasms 180Melanoma 171Squamous Cell Carcinoma of Head and Neck 140Endometrial Neoplasms 140Head and Neck Neoplasms 124Carcinoma, Renal Cell 118Uterine Cervical Neoplasms 104Esophageal Neoplasms 97Urinary Bladder Neoplasms 92Small Cell Lung Carcinoma 87Sarcoma 85Colonic Neoplasms 80Carcinoma, Hepatocellular 62Carcinoma, Transitional Cell 61Kidney Neoplasms 51Advanced Breast Cancer 51Cholangiocarcinoma 50Liver Neoplasms 47Brain Neoplasms 43Mesothelioma 37

Interventions

olaparib 1Paclitaxel 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Metastatic Breast Cancer × Breast × Clear all
NCT00516724 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

AstraZeneca

Phase 1 Completed
189 enrolled
BreastGynecologic

Triple Negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡